Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: Potential role in obesity

Journal of Hypertension

Volumn 32, Issue 5, 2014, Pages 1104-1114

  Martínez Martínez, Ernesto ^a   Jurado López, Raquel ^a   Valero Muñoz, María ^a   Bartolomé, María Visitación ^a   Ballesteros, Sandra ^a   Luaces, María ^b   Briones, Ana María ^c   López Andrés, Natalia ^d   Miana, María ^a   Cachofeiro, Victoria ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Atención Primaria Y Promoción de La Salud   (Spain)

Author keywords

cardiac myofibroblasts; fibrosis; galectin 3; leptin; mTOR pathway; obesity; oxidative stress

Indexed keywords

AMINE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; GALECTIN 3; GELATINASE A; HYDROETHIDINE; LEPTIN; MELATONIN; N ACETYLLACTOSAMINE; OXYGEN; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; FAT INTAKE; MTOR PROTEIN, RAT; SUPEROXIDE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC STRUCTURE; CARDIAC SYSTOLIC FUNCTION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; LIPID DIET; MALE; MEDIATOR; MYOFIBROBLAST; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; WISTAR RAT; ADMINISTRATION AND DOSAGE; ANIMAL; CARDIOMYOPATHY; CELL CULTURE; FAT INTAKE; FIBROSIS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; CARDIOMYOPATHIES; CELLS, CULTURED; DIETARY FATS; FIBROSIS; GALECTIN 3; LEPTIN; MALE; OBESITY; OXIDATIVE STRESS; PHOSPHORYLATION; RATS; RATS, WISTAR; SUPEROXIDES; TOR SERINE-THREONINE KINASES;

EID: 84898411494     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000149     Document Type: Article

References (65)

1. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA. Impact of obesity on cardiovascular disease. Med Clin North Am 2011; 95:919-937.
2. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9:88.
3. Mandry D, Eschalier R, Kearney-Schwartz A, Rossignol P, Joly L, Djaballah W, et al. Comprehensive MRI analysis of early cardiac and vascular remodeling in middle-aged patients with abdominal obesity. J Hypertens 2012; 30:567-573.
4. Luaces M, Cachofeiro V, Garcia-Munoz-Najar A, Medina M, Gonzalez N, Cancer E, et al. Anatomical and functional alterations of the heart in morbid obesity. Changes after bariatric surgery. Rev Esp Cardiol 2012; 65:14-21.
5. Litwin SE. Cardiac remodeling in obesity: time for a new paradigm. JACC Cardiovasc Imaging 2010; 3:275-277.
6. Hayden MR, Chowdhury N, Govindarajan G, Karuparthi PR, Habibi J, Sowers JR. Myocardial myocyte remodeling and fibrosis in the cardiometabolic syndrome. J Cardiometab Syndr 2006; 1:326-333.
7. Panchal SK, Poudyal H, Iyer A, Nazer R, Alam A, Diwan V, et al. High-carbohydrate high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol 2011; 57:51-64.
8. Schram K, Sweeney G. Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure. Trends Cardiovasc Med 2008; 18:199-205.
9. Iacobellis G, Malavazos AE, Corsi MM. Epicardial fat: from the biomolecular aspects to the clinical practice. Int J Biochem Cell Biol 2011; 43:1651-1654.
10. Rahmouni K. Leptin-induced sympathetic nerve activation: signaling mechanisms and cardiovascular consequences in obesity. Curr Hypertens Rev 2010; 6:104-209.
11. Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005; 54:2012-2018.
12. Correia ML, Haynes WG, Rahmouni K, Morgan DA, Sivitz WI, Mark AL. The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002; 51:439-442.
13. Schram K, Wong MM, Palanivel R, No EK, Dixon IM, Sweeney G. Increased expression and cell surface localization of MT1-MMP plays a role in stimulation of MMP-2 activity by leptin in neonatal rat cardiac myofibroblasts. J Mol Cell Cardiol 2008; 44:874-881.
14. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failureprone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110:3121-3128.
15. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11:811-817.
16. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008; 28: 433-440.
17. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48:1217-1224.
18. Lopez-Andres N, Rossignol P, Iraqi W, Fay R, Nuee J, Ghio S, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012; 14:74-81.
19. Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007; 31:655-662.
20. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272:55-64.
21. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010; 95:1404-1411.
22. de las Heras N, Martin-Fernandez B, Miana M, Ballesteros S, Oubina MP, Lopez-Farre AJ, et al. The protective effect of irbesartan in rats fed a high fat diet is associated with modification of leptin-adiponectin imbalance. J Hypertens Suppl 2009; 27:S37-S41.
23. Martin R, Miana M, Jurado-Lopez R, Martinez-Martinez E, Gomez- Hurtado N, Delgado C, et al. DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy. PLoS One 2012; 7:e41545.
24. Grotendorst GR, Duncan MR. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J 2005; 19:729-738.
25. Calvier L, Miana M, Reboul P, Cachofeiro V, Martínez- Martínez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013; 33:67-75; 2012.
26. Zibadi S, Cordova F, Slack EH, Watson RR, Larson DF. Leptin's regulation of obesity-induced cardiac extracellular matrix remodeling. Cardiovasc Toxicol 2011; 11:325-333.
27. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, et al. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007; 56:641-646.
28. Iwanaga Y, Aoyama T, Kihara Y, Onozawa Y, Yoneda T, Sasayama S. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 2002; 39:1384-1391.
29. Han DC, Isono M, Chen S, Casaretto A, Hong SW, Wolf G, Ziyadeh FN. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression. Kidney Int 2001; 59:1315-1323.
30. Marra F, Navari N, Vivoli E, Galastri S, Provenzano A. Modulation of liver fibrosis by adipokines. Dig Dis 2011; 29:371-376.
31. Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol 2006; 151:175-183.
32. de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996; 93:259-265.
33. Oliveira Junior SA, Padovani CR, Rodrigues SA, Silva NR, Martinez PF, Campos DH, et al. Extensive impact of saturated fatty acids on metabolic and cardiovascular profile in rats with diet-induced obesity: a canonical analysis. Cardiovasc Diabetol 2013; 12:65.
34. Mostarda C, Moraes-Silva IC, Salemi VM, Machi JF, Rodrigues B, De AK, et al. Exercise training prevents diastolic dysfunction induced by metabolic syndrome in rats. Clinics (Sao Paulo) 2012; 67:815-820.
35. Jeckel KM, Miller KE, Chicco AJ, Chapman PL, Mulligan CM, Falcone PH, et al. The role of dietary fatty acids in predicting myocardial structure in fat-fed rats. Lipids Health Dis 2011; 10:92.
36. Jeckel KM, Veeramachaneni DN, Chicco AJ, Chapman PL, Mulligan CM, Hegarty JR, et al. Docosahexaenoic acid supplementation does not improve Western diet-induced cardiomyopathy in rats. PLoS One 2012; 7:e51994.
37. Carroll JF, Zenebe WJ, Strange TB. Cardiovascular function in a rat model of diet-induced obesity. Hypertension 2006; 48:65-72.
38. Barretti DL, Magalhaes FC, Fernandes T, do Carmo EC, Rosa KT, Irigoyen MC, et al. Effects of aerobic exercise training on cardiac renin-angiotensin system in an obese Zucker rat strain. PLoS One 2012; 7:e46114.
39. Collier P, Watson CJ, van Es MH, Phelan D, McGorrian C, Tolan M, et al. Getting to the heart of cardiac remodeling; how collagen subtypes may contribute to phenotype. J Mol Cell Cardiol 2012; 52:148-153.
40. Azibani F, Benard L, Schlossarek S, Merval R, Tournoux F, Fazal L, et al. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension 2012; 59:1179-1187.
41. Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K, et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004; 44:904-913.
42. Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, Zhang L, et al. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 2007; 71:144-152.
43. Miana M, de Las HN, Rodriguez C, Sanz-Rosa D, Martin-Fernandez B, Mezzano S, et al. Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPAR-gamma). J Physiol Pharmacol 2011; 62:87-94.
44. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007; 74:196-206.
45. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276:25096-25100.
46. He WH, Li B, Zhu X, Zhang KH, Li BM, Liu ZJ, et al. The role and mechanism of NADPH oxidase in leptin-induced reactive oxygen species production in hepatic stellate cells. Zhonghua Gan Zang Bing Za Zhi 2010; 18:849-854.
47. Fortuno A, Bidegain J, Baltanas A, Moreno MU, Montero L, Landecho MF, et al. Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications. J Hypertens 2010; 28:1944- 1950.
48. Reiter RJ, Tan DX. Melatonin: an antioxidant in edible plants. Ann N Y Acad Sci 2002; 957:341-344.
49. Kim BC, Shon BS, Ryoo YW, Kim SP, Lee KS. Melatonin reduces X-ray irradiation-induced oxidative damages in cultured human skin fibroblasts. J Dermatol Sci 2001; 26:194-200.
50. Yu M, Zheng Y, Sun HX, Yu DJ. Inhibitory effects of enalaprilat on rat cardiac fibroblast proliferation via ROS/P38MAPK/TGF-beta1 signaling pathway. Molecules 2012; 17:2738-2751.
51. Shyu KG, Wang BW, Chen WJ, Kuan P, Lin CM. Angiotensin II mediates urotensin II expression by hypoxia in cultured cardiac fibroblast. Eur J Clin Invest 2012; 42:17-26.
52. Khong FL, Zhang Y, Edgley AJ, Qi W, Connelly KA, Woodman OL, et al. 3', 4'-Dihydroxyflavonol antioxidant attenuates diastolic dysfunction and cardiac remodeling in streptozotocin-induced diabetic m(Ren2)27 rats. PLoS One 2011; 6:e22777.
53. Liu C, Cao F, Tang QZ, Yan L, Dong YG, Zhu LH, et al. Allicin protects against cardiac hypertrophy and fibrosis via attenuating reactive oxygen species-dependent signaling pathways. J Nutr Biochem 2010; 21:1238-1250.
54. Yu SY, Liu L, Li PU, Li J. Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy. Thorac Cardiovasc Surg 2013; 61:223-228.
55. Vilahur G, Juan-Babot O, Pena E, Onate B, Casani L, Badimon L. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol 2011; 50:522-533.
56. Aoyagi T, Kusakari Y, Xiao CY, Inouye BT, Takahashi M, Scherrer- Crosbie M, et al. Cardiac mTOR protects the heart against ischemiareperfusion injury. Am J Physiol Heart Circ Physiol 2012; 303:H75-H85.
57. Xu X, Hu X, Lu Z, Zhang P, Zhao L, Wessale JL, et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail 2008; 14:746-753.
58. Schenkel PC, Tavares AM, Fernandes RO, Diniz GP, Bertagnolli M, da Rosa Araujo AS, et al. Redox-sensitive prosurvival and proapoptotic protein expression in the myocardial remodeling postinfarction in rats. Mol Cell Biochem 2010; 341:1-8.
59. Schenkel PC, Tavares AM, Fernandes RO, Diniz GP, Ludke AR, Ribeiro MF, et al. Time course of hydrogen peroxide-thioredoxin balance and its influence on the intracellular signalling in myocardial infarction. Exp Physiol 2012; 97:741-749.
60. Zeidan A, Hunter JC, Javadov S, Karmazyn M. mTOR mediates RhoA-dependent leptin-induced cardiomyocyte hypertrophy. Mol Cell Biochem 2011; 352:99-108.
61. Rodriguez A, Catalan V, Gomez-Ambrosi J, Garcia-Navarro S, Rotellar F, Valenti V, et al. Insulin- and leptin-mediated control of aquaglyceroporins in human adipocytes and hepatocytes is mediated via the PI3K/Akt/mTOR signaling cascade. J Clin Endocrinol Metab 2011; 96:E586-E597.
62. Maya-Monteiro CM, Bozza PT. Leptin and mTOR: partners in metabolism and inflammation. Cell Cycle 2008; 7:1713-1717.
63. Shan J, Nguyen TB, Totary-Jain H, Dansky H, Marx SO, Marks AR. Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proc Natl Acad Sci U S A 2008; 105:19006-19011.
64. Fernandes Bertocchi AP, Campanhole G, Wang PH, Goncalves GM, Damiao MJ, Cenedeze MA, et al. A role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int 2008; 21:999-1007.
65. Alves CM, Silva DA, Azzolini AE, Marzocchi-Machado CM, Lucisano- Valim YM, Roque-Barreira MC, Mineo JR. Galectin-3 is essential for reactive oxygen species production by peritoneal neutrophils from mice infected with a virulent strain of Toxoplasma gondii. Parasitology 2013; 140:210-219